Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.MIRN · Entity 7801 | Director | June 29, 2016 | September 06, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date June 29, 2016 · Filed September 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2026-06-29 | Direct | 10,000 |
Reported balance
After 2016-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-06-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akoya Biosciences, Inc.
Report date July 08, 2025 · Filed July 10, 2025
Section 16 reporting ended · disclosed 2025-07-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 1
1 source rowRow 1 · 2025-07-08 · Other · Disposed 984,513 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.95 · Expires 2031-05-21 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-08 · Other · Disposed 16,860 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.24 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-08 · Other · Disposed 30,549 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2033-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-08 · Other · Disposed 56,322 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-08 · Other · Disposed 50,000 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3: Disposition of options pursuant to Merger Agreement.
F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2025 Filed Jul 10, 2025 20:38 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001062993-25-012726 · form4.xml · derivative · entry 5 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:38 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 56,322 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001062993-25-012726 · form4.xml · derivative · entry 4 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:38 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 30,549 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001062993-25-012726 · form4.xml · derivative · entry 3 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:38 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (Right to Buy) · Derivative | 16,860 | $0.00 Strike: $21.95 | $0.00 |
DisclosureSEC source: 0001062993-25-012726 · form4.xml · derivative · entry 2 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,860 shares Expires 2031-05-21 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:38 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherCommon Stock | 984,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-25-012726 · form4.xml · nonDerivative · entry 1 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2 · price: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 17:56 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-24-068748 · tm2416554-4_4seq1.xml · derivative · entry 1 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 4, 2025, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 18:16 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | PurchaseCommon Stock | 203,388 | $5.00 | $1,016,940.00 |
DisclosureSEC source: 0001104659-23-070481 · tm2318472-3_4seq1.xml · nonDerivative · entry 1 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 984,513 Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 17:54 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy) · Derivative | 56,322 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001104659-23-068165 · tm2317841-2_4seq1.xml · derivative · entry 1 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,322 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:07 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy · Derivative | 30,549 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001104659-22-068078 · tm2217652-6_4seq1.xml · derivative · entry 2 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,549 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| May 21, 2021 Filed May 25, 2021 21:56 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy · Derivative | 16,860 | $0.00 Strike: $21.95 | $0.00 |
DisclosureSEC source: 0001104659-21-072014 · tm2117585-5_4seq1.xml · derivative · entry 2 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,860 Underlying: Common Stock · 16,860 shares Expires 2031-05-21 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) May 21, 2022, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| June 29, 2016 Filed Sep 6, 2016 22:25 UTC | SYNLOGIC, INC. MIRN · Entity 7801 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001140361-16-078991 · doc1.xml · derivative · entry 1 Winkler Matthew · CIK 0001652067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-29 F1 · derivative.exercise_date: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.